| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 16 | 2023 | 88 | 4.680 |
Why?
|
| Crohn Disease | 8 | 2023 | 45 | 2.130 |
Why?
|
| Gastrointestinal Microbiome | 10 | 2023 | 181 | 1.840 |
Why?
|
| Colitis, Ulcerative | 7 | 2022 | 68 | 1.720 |
Why?
|
| Intestinal Mucosa | 12 | 2019 | 224 | 1.410 |
Why?
|
| Diet | 6 | 2019 | 172 | 1.300 |
Why?
|
| Dietary Carbohydrates | 3 | 2020 | 11 | 1.170 |
Why?
|
| Colon | 9 | 2019 | 149 | 1.130 |
Why?
|
| Particulate Matter | 3 | 2018 | 22 | 1.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2019 | 223 | 1.060 |
Why?
|
| Gastrointestinal Tract | 5 | 2018 | 56 | 1.030 |
Why?
|
| Microbiota | 9 | 2023 | 105 | 0.980 |
Why?
|
| Metagenome | 4 | 2015 | 22 | 0.820 |
Why?
|
| Diverticulitis | 1 | 2021 | 2 | 0.780 |
Why?
|
| Adiposity | 1 | 2021 | 47 | 0.770 |
Why?
|
| Adipose Tissue | 1 | 2021 | 74 | 0.760 |
Why?
|
| Humans | 47 | 2023 | 29815 | 0.710 |
Why?
|
| Immunosuppressive Agents | 4 | 2019 | 135 | 0.710 |
Why?
|
| Intestines | 4 | 2017 | 108 | 0.680 |
Why?
|
| Colitis, Collagenous | 1 | 2019 | 1 | 0.660 |
Why?
|
| Inhalation Exposure | 2 | 2018 | 6 | 0.660 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2018 | 5 | 0.650 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2017 | 45 | 0.640 |
Why?
|
| Air Pollutants | 1 | 2018 | 12 | 0.620 |
Why?
|
| RNA, Ribosomal, 16S | 4 | 2017 | 57 | 0.620 |
Why?
|
| Adult | 22 | 2023 | 8741 | 0.610 |
Why?
|
| Bacteria | 6 | 2017 | 76 | 0.610 |
Why?
|
| Complementary Therapies | 1 | 2017 | 14 | 0.600 |
Why?
|
| ABO Blood-Group System | 1 | 2017 | 7 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 119 | 0.590 |
Why?
|
| Female | 27 | 2023 | 16412 | 0.550 |
Why?
|
| Diverticulum | 1 | 2016 | 3 | 0.550 |
Why?
|
| Methane | 1 | 2016 | 4 | 0.550 |
Why?
|
| Middle Aged | 21 | 2023 | 9960 | 0.550 |
Why?
|
| Ethanol | 3 | 2015 | 134 | 0.530 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2014 | 101 | 0.520 |
Why?
|
| Male | 27 | 2021 | 15851 | 0.520 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2023 | 190 | 0.520 |
Why?
|
| Feces | 10 | 2019 | 97 | 0.510 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 6 | 0.490 |
Why?
|
| Hepatitis B | 1 | 2014 | 18 | 0.490 |
Why?
|
| Vaccination | 1 | 2014 | 41 | 0.480 |
Why?
|
| HIV Infections | 4 | 2018 | 997 | 0.470 |
Why?
|
| Dietary Proteins | 3 | 2017 | 22 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 129 | 0.440 |
Why?
|
| Capsule Endoscopy | 1 | 2012 | 3 | 0.430 |
Why?
|
| Gastrointestinal Transit | 1 | 2012 | 11 | 0.430 |
Why?
|
| Intestine, Small | 1 | 2012 | 34 | 0.410 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2023 | 9 | 0.390 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 73 | 0.390 |
Why?
|
| Dysbiosis | 4 | 2015 | 64 | 0.390 |
Why?
|
| Oxidants | 1 | 2011 | 29 | 0.380 |
Why?
|
| Alcoholism | 1 | 2012 | 83 | 0.380 |
Why?
|
| Cell Membrane Permeability | 1 | 2011 | 59 | 0.380 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 352 | 0.360 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2009 | 11 | 0.340 |
Why?
|
| Dietary Fiber | 3 | 2020 | 20 | 0.340 |
Why?
|
| Endotoxemia | 1 | 2009 | 29 | 0.340 |
Why?
|
| Central Nervous System Depressants | 1 | 2009 | 24 | 0.340 |
Why?
|
| Polymerase Chain Reaction | 4 | 2017 | 164 | 0.310 |
Why?
|
| Starch | 2 | 2019 | 7 | 0.310 |
Why?
|
| Inflammation | 4 | 2018 | 347 | 0.300 |
Why?
|
| Animals | 9 | 2019 | 4638 | 0.280 |
Why?
|
| Serum Albumin | 1 | 2006 | 24 | 0.270 |
Why?
|
| Aspartate Aminotransferases | 1 | 2006 | 19 | 0.270 |
Why?
|
| Alanine Transaminase | 1 | 2006 | 23 | 0.270 |
Why?
|
| Colon, Sigmoid | 2 | 2017 | 18 | 0.270 |
Why?
|
| Aged | 11 | 2019 | 9620 | 0.270 |
Why?
|
| Quality of Life | 3 | 2020 | 677 | 0.260 |
Why?
|
| Biopsy | 6 | 2018 | 239 | 0.260 |
Why?
|
| Air Pollution | 2 | 2018 | 17 | 0.250 |
Why?
|
| Mice | 5 | 2018 | 1628 | 0.250 |
Why?
|
| Metabolome | 2 | 2015 | 16 | 0.240 |
Why?
|
| Volatile Organic Compounds | 2 | 2015 | 10 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 435 | 0.230 |
Why?
|
| Logistic Models | 2 | 2016 | 410 | 0.220 |
Why?
|
| Case-Control Studies | 5 | 2017 | 641 | 0.220 |
Why?
|
| Veterans | 1 | 2023 | 63 | 0.210 |
Why?
|
| Remission Induction | 2 | 2020 | 103 | 0.200 |
Why?
|
| Gastrointestinal Agents | 1 | 2002 | 13 | 0.200 |
Why?
|
| alpha-Synuclein | 2 | 2015 | 139 | 0.200 |
Why?
|
| Subcutaneous Fat | 1 | 2021 | 10 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 155 | 0.200 |
Why?
|
| Retrospective Studies | 3 | 2016 | 3325 | 0.190 |
Why?
|
| Absorptiometry, Photon | 1 | 2021 | 84 | 0.190 |
Why?
|
| Gene Expression Profiling | 3 | 2018 | 159 | 0.190 |
Why?
|
| Dietary Fats | 2 | 2017 | 22 | 0.190 |
Why?
|
| Celiac Disease | 2 | 2016 | 9 | 0.190 |
Why?
|
| Phylogeny | 2 | 2017 | 63 | 0.180 |
Why?
|
| Young Adult | 5 | 2019 | 1966 | 0.180 |
Why?
|
| Ultrasonography | 1 | 2021 | 224 | 0.170 |
Why?
|
| Constipation | 2 | 2017 | 22 | 0.170 |
Why?
|
| Firmicutes | 1 | 2019 | 6 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 47 | 0.160 |
Why?
|
| Butyrates | 1 | 2019 | 19 | 0.160 |
Why?
|
| Mucous Membrane | 1 | 2019 | 40 | 0.160 |
Why?
|
| Fatty Acids | 2 | 2019 | 39 | 0.160 |
Why?
|
| Interferon Type I | 1 | 2018 | 19 | 0.160 |
Why?
|
| Reactive Oxygen Species | 2 | 2011 | 130 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 92 | 0.160 |
Why?
|
| Ileum | 3 | 2017 | 24 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2018 | 39 | 0.150 |
Why?
|
| Prevalence | 2 | 2022 | 494 | 0.150 |
Why?
|
| Micronutrients | 1 | 2017 | 4 | 0.150 |
Why?
|
| Hospitalization | 2 | 2023 | 319 | 0.150 |
Why?
|
| Adolescent | 2 | 2015 | 2332 | 0.150 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 10 | 0.150 |
Why?
|
| Food Additives | 1 | 2017 | 6 | 0.150 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2017 | 19 | 0.150 |
Why?
|
| Wound Healing | 1 | 2019 | 168 | 0.150 |
Why?
|
| Discriminant Analysis | 1 | 2017 | 9 | 0.150 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 38 | 0.150 |
Why?
|
| Kupffer Cells | 1 | 2017 | 2 | 0.150 |
Why?
|
| Defecation | 1 | 2017 | 3 | 0.150 |
Why?
|
| Enteral Nutrition | 1 | 2017 | 50 | 0.150 |
Why?
|
| Candida | 1 | 2017 | 16 | 0.150 |
Why?
|
| Hepatocytes | 1 | 2017 | 10 | 0.150 |
Why?
|
| Prebiotics | 1 | 2017 | 16 | 0.150 |
Why?
|
| Microspheres | 1 | 2017 | 31 | 0.150 |
Why?
|
| Sulfur-Reducing Bacteria | 1 | 2017 | 1 | 0.140 |
Why?
|
| Demography | 1 | 2017 | 78 | 0.140 |
Why?
|
| Biodiversity | 1 | 2017 | 37 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 1 | 2017 | 82 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 433 | 0.140 |
Why?
|
| Multiple System Atrophy | 1 | 2017 | 42 | 0.140 |
Why?
|
| Breath Tests | 1 | 2016 | 11 | 0.140 |
Why?
|
| Colonoscopy | 1 | 2016 | 50 | 0.130 |
Why?
|
| Zonula Occludens-1 Protein | 2 | 2017 | 15 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 82 | 0.130 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 282 | 0.130 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 10 | 0.130 |
Why?
|
| Risk Factors | 4 | 2021 | 2465 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 194 | 0.130 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 85 | 0.130 |
Why?
|
| Chicago | 2 | 2017 | 867 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 970 | 0.130 |
Why?
|
| Rheumatic Diseases | 1 | 2016 | 56 | 0.130 |
Why?
|
| Caudovirales | 1 | 2015 | 2 | 0.130 |
Why?
|
| Microviridae | 1 | 2015 | 2 | 0.130 |
Why?
|
| Biomarkers | 3 | 2014 | 704 | 0.130 |
Why?
|
| Pattern Recognition, Automated | 1 | 2015 | 9 | 0.120 |
Why?
|
| Permeability | 3 | 2014 | 139 | 0.120 |
Why?
|
| Immunity, Mucosal | 1 | 2015 | 29 | 0.120 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 9 | 0.120 |
Why?
|
| Serologic Tests | 1 | 2014 | 14 | 0.120 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2014 | 6 | 0.120 |
Why?
|
| Particle Size | 2 | 2011 | 69 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2014 | 53 | 0.120 |
Why?
|
| Infant, Premature | 1 | 2016 | 184 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 67 | 0.120 |
Why?
|
| Adalimumab | 1 | 2014 | 16 | 0.120 |
Why?
|
| Mastectomy | 1 | 2014 | 19 | 0.120 |
Why?
|
| Parkinson Disease | 2 | 2015 | 1184 | 0.120 |
Why?
|
| Diarrhea | 1 | 2014 | 47 | 0.120 |
Why?
|
| Interleukin-6 | 2 | 2011 | 109 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 110 | 0.120 |
Why?
|
| Photoperiod | 1 | 2014 | 44 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2014 | 85 | 0.120 |
Why?
|
| Solid Phase Microextraction | 1 | 2013 | 4 | 0.120 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2016 | 182 | 0.110 |
Why?
|
| Artifacts | 1 | 2013 | 34 | 0.110 |
Why?
|
| Hypertension | 1 | 2016 | 272 | 0.110 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2016 | 163 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 142 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2013 | 50 | 0.110 |
Why?
|
| Age Factors | 1 | 2016 | 853 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 532 | 0.110 |
Why?
|
| Fatty Acids, Volatile | 3 | 2019 | 29 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 200 | 0.110 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2012 | 22 | 0.110 |
Why?
|
| Cytokines | 3 | 2017 | 350 | 0.100 |
Why?
|
| Oxidative Stress | 2 | 2011 | 131 | 0.100 |
Why?
|
| Enteric Nervous System | 1 | 2011 | 5 | 0.100 |
Why?
|
| District of Columbia | 1 | 2011 | 4 | 0.100 |
Why?
|
| Occludin | 1 | 2011 | 13 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 778 | 0.100 |
Why?
|
| Electric Impedance | 1 | 2011 | 25 | 0.100 |
Why?
|
| Tight Junctions | 1 | 2011 | 28 | 0.100 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2011 | 4 | 0.100 |
Why?
|
| Phosphoproteins | 1 | 2011 | 28 | 0.100 |
Why?
|
| Caco-2 Cells | 1 | 2011 | 55 | 0.100 |
Why?
|
| Cell Death | 1 | 2011 | 62 | 0.100 |
Why?
|
| Blood Coagulation | 1 | 2011 | 21 | 0.100 |
Why?
|
| Child | 1 | 2015 | 1377 | 0.100 |
Why?
|
| Inpatients | 1 | 2012 | 141 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2011 | 110 | 0.090 |
Why?
|
| Mitochondria | 1 | 2011 | 84 | 0.090 |
Why?
|
| Circadian Rhythm | 1 | 2014 | 283 | 0.090 |
Why?
|
| Pneumonia | 1 | 2011 | 67 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2011 | 177 | 0.090 |
Why?
|
| Peptide Mapping | 1 | 2009 | 6 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2022 | 508 | 0.090 |
Why?
|
| Glucose | 1 | 2009 | 60 | 0.080 |
Why?
|
| Intestinal Absorption | 1 | 2009 | 42 | 0.080 |
Why?
|
| Neurons | 1 | 2011 | 380 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 463 | 0.080 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2007 | 4 | 0.080 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 18 | 0.070 |
Why?
|
| Colonic Pouches | 1 | 2007 | 4 | 0.070 |
Why?
|
| Pouchitis | 1 | 2007 | 5 | 0.070 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2007 | 6 | 0.070 |
Why?
|
| Rats | 1 | 2009 | 876 | 0.070 |
Why?
|
| DNA, Bacterial | 2 | 2017 | 49 | 0.070 |
Why?
|
| Plant Preparations | 1 | 2006 | 9 | 0.070 |
Why?
|
| Phytotherapy | 1 | 2006 | 15 | 0.070 |
Why?
|
| Antioxidants | 1 | 2006 | 61 | 0.070 |
Why?
|
| Health Status Disparities | 2 | 2017 | 70 | 0.070 |
Why?
|
| Physical Fitness | 1 | 2006 | 59 | 0.070 |
Why?
|
| Endoscopy, Digestive System | 1 | 2003 | 9 | 0.060 |
Why?
|
| Esophagitis | 1 | 2003 | 11 | 0.060 |
Why?
|
| Eosinophilia | 1 | 2003 | 47 | 0.060 |
Why?
|
| Recurrence | 2 | 2020 | 354 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 4930 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2003 | 43 | 0.050 |
Why?
|
| Digestive System | 1 | 2002 | 16 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2002 | 25 | 0.050 |
Why?
|
| Exercise | 1 | 2006 | 474 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2003 | 109 | 0.050 |
Why?
|
| Uncertainty | 1 | 2021 | 8 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2002 | 91 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 270 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 143 | 0.050 |
Why?
|
| Meat | 1 | 2020 | 2 | 0.040 |
Why?
|
| Food, Organic | 1 | 2020 | 3 | 0.040 |
Why?
|
| Calcium, Dietary | 1 | 2020 | 12 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 237 | 0.040 |
Why?
|
| Pain | 1 | 2023 | 397 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 1641 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 58 | 0.040 |
Why?
|
| Steroids | 1 | 2019 | 22 | 0.040 |
Why?
|
| Solanum tuberosum | 1 | 2019 | 2 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 401 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 384 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2020 | 190 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 349 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 98 | 0.040 |
Why?
|
| DNA, Ribosomal | 1 | 2017 | 12 | 0.040 |
Why?
|
| Anxiety | 1 | 2019 | 157 | 0.040 |
Why?
|
| Fermentation | 1 | 2017 | 11 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 334 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2017 | 98 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 111 | 0.040 |
Why?
|
| Viral Load | 1 | 2017 | 208 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 48 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2017 | 33 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2017 | 309 | 0.030 |
Why?
|
| Sigmoidoscopy | 1 | 2016 | 8 | 0.030 |
Why?
|
| Birth Weight | 1 | 2016 | 34 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 522 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2015 | 1952 | 0.030 |
Why?
|
| Gestational Age | 1 | 2016 | 75 | 0.030 |
Why?
|
| Employment | 1 | 2016 | 42 | 0.030 |
Why?
|
| Income | 1 | 2016 | 77 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 129 | 0.030 |
Why?
|
| Protein Folding | 1 | 2015 | 22 | 0.030 |
Why?
|
| Alkanes | 1 | 2015 | 3 | 0.030 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 4 | 0.030 |
Why?
|
| Terpenes | 1 | 2015 | 4 | 0.030 |
Why?
|
| Fatty Alcohols | 1 | 2015 | 6 | 0.030 |
Why?
|
| Sulfides | 1 | 2015 | 12 | 0.030 |
Why?
|
| Disulfides | 1 | 2015 | 12 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2015 | 6 | 0.030 |
Why?
|
| Metabolomics | 1 | 2014 | 23 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 329 | 0.030 |
Why?
|
| Lactobacillus | 1 | 2014 | 20 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 22 | 0.030 |
Why?
|
| Bacterial Translocation | 1 | 2014 | 35 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 297 | 0.030 |
Why?
|
| Dietary Sucrose | 1 | 2014 | 7 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2014 | 17 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 216 | 0.030 |
Why?
|
| Infant | 1 | 2016 | 542 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2013 | 14 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 26 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 618 | 0.030 |
Why?
|
| Light | 1 | 2014 | 77 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 558 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 802 | 0.030 |
Why?
|
| Algorithms | 1 | 2015 | 400 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 1823 | 0.020 |
Why?
|
| Tyrosine | 1 | 2011 | 25 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1462 | 0.020 |
Why?
|
| Adipose Tissue, White | 1 | 2011 | 2 | 0.020 |
Why?
|
| Fibrin | 1 | 2011 | 4 | 0.020 |
Why?
|
| Cities | 1 | 2011 | 14 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 744 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 108 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 1859 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 273 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 2011 | 149 | 0.020 |
Why?
|
| Lung | 1 | 2011 | 158 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2007 | 5 | 0.020 |
Why?
|
| Biofilms | 1 | 2007 | 15 | 0.020 |
Why?
|
| Herbal Medicine | 1 | 2006 | 2 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 102 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 230 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 411 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2006 | 75 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 337 | 0.020 |
Why?
|
| Asthma | 1 | 2006 | 137 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 683 | 0.010 |
Why?
|
| Histamine H1 Antagonists | 1 | 2003 | 5 | 0.010 |
Why?
|
| Budesonide | 1 | 2003 | 5 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 2003 | 7 | 0.010 |
Why?
|
| Histamine H2 Antagonists | 1 | 2003 | 7 | 0.010 |
Why?
|
| Azathioprine | 1 | 2003 | 9 | 0.010 |
Why?
|
| Esophageal Perforation | 1 | 2003 | 7 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2003 | 13 | 0.010 |
Why?
|
| Proton Pump Inhibitors | 1 | 2003 | 13 | 0.010 |
Why?
|
| Gastrointestinal Motility | 1 | 2003 | 14 | 0.010 |
Why?
|
| Proton Pumps | 1 | 2003 | 14 | 0.010 |
Why?
|
| Catheterization | 1 | 2003 | 51 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2003 | 45 | 0.010 |
Why?
|
| Gastroesophageal Reflux | 1 | 2003 | 34 | 0.010 |
Why?
|
| Prednisone | 1 | 2003 | 68 | 0.010 |
Why?
|
| Eosinophils | 1 | 2003 | 47 | 0.010 |
Why?
|
| Esophagus | 1 | 2003 | 59 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2006 | 364 | 0.010 |
Why?
|
| Gastric Acid | 1 | 2002 | 9 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 399 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2002 | 149 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2002 | 40 | 0.010 |
Why?
|
| Acute Disease | 1 | 2002 | 225 | 0.010 |
Why?
|
| Food Hypersensitivity | 1 | 2002 | 54 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2003 | 3561 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 2005 | 0.010 |
Why?
|